Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

ZENOTECH LABORATORIES LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹37.80
at close · 28 Oct 2026
▼ 0.60 (-1.56%)

Latest filings

  1. Revenue falls, loss widens and operating cash flow turns negative · Results
  2. Zenotech reports loss as September quarter revenue falls 40 percent · Results
  3. Board meeting on Oct 28 to approve Q2 FY26 financial results · Results
All filings ↓
Ask Nexa about ZENOTECH LABORATORIES LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹40 Cr over the trailing twelve months.

Market Cap
₹231 Cr
P / E (TTM)
378.0×
EV / EBITDA
17.7×
Div Yield
—
Growth
12.0%▲
Revenue 5y CAGR
PAT — · EBITDA +10.7%
Quality
12.0%▲
ROCE (5y median)
ROE 9.2% (5y median) · margin 28.6%
Leverage
0.00·
Debt / Equity · low
Net cash ₹30 Cr
Revenue FY21→FY26
1.8×▲
Margin +2.7 pts
₹22 Cr → ₹40 Cr
Cash conversion
1.50×▲
Operating cash ÷ profit · 5 yrs
₹70 Cr on ₹47 Cr
Moves on a normal day
1.38%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#156/158
P/B#66/163
ROCE#131/183
ROE#145/166
Debt / Equity#1/166
EBITDA margin#125/165
Revenue growth#140/161
Profit growth#155/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 12% a year over 5 years
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Over 5 years it reported ₹47 Cr of profit and ₹70 Cr of operating cash — 1.50×
Profit is converting into cash
Concerns
Erratic profits — up in only 1 of the last 5 years

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ZENOTECH LABORATORIES LTD.'s filed financials and exchange disclosures

What does ZENOTECH LABORATORIES LTD. do?

ZENOTECH LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is ZENOTECH LABORATORIES LTD. profitable?

No. Over the trailing twelve months ZENOTECH LABORATORIES LTD. reported a net loss of ₹1.07 Cr on revenue of ₹40 Cr.

Does ZENOTECH LABORATORIES LTD. pay a dividend?

Not in the latest reported year — ZENOTECH LABORATORIES LTD.'s dividend payout for FY26 was nil.

Is ZENOTECH LABORATORIES LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹30 Cr of cash.

Is ZENOTECH LABORATORIES LTD. expensive compared with its peers?

On trailing P/E, ZENOTECH LABORATORIES LTD. ranks 156 of 158 in Pharmaceuticals — cheaper than 1% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the ZENOTECH LABORATORIES LTD. share price move in a day?

On a typical session ZENOTECH LABORATORIES LTD. moves 1.38% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track ZENOTECH LABORATORIES LTD.'s announcements?

Every NSE and BSE filing by ZENOTECH LABORATORIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.